Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Scisparc Ltd (SPRC)

Scisparc Ltd (SPRC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder Globe Newswire - Mon Aug 8, 2022

The trial's objectives are to evaluate the safety, tolerability and efficacy of SciSparc's SCI-210 in children and adolescents with ASD TEL AVIV,...

SPRC : 1.2400 (+2.48%)
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome Globe Newswire - Mon Aug 1, 2022

The addition of a U.S. site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need TEL...

SPRC : 1.2400 (+2.48%)
SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome Globe Newswire - Fri Jul 8, 2022

TEL AVIV, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical...

SPRC : 1.2400 (+2.48%)
SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility Globe Newswire - Thu Jul 7, 2022

The new facility will serve the JV’s development of potential cancer drugs TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:...

SPRC : 1.2400 (+2.48%)
Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd. AccessWire - Thu Jul 7, 2022

NEW YORK, NY / ACCESSWIRE / July 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a...

SPRC : 1.2400 (+2.48%)
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions FinancialNewsMedia - Wed Jun 29, 2022

Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in...

SPRC : 1.2400 (+2.48%)
DNLI : 15.04 (-3.34%)
SAGE : 13.80 (-1.43%)
SAVA : 21.68 (+4.53%)
ICPT : 19.00 (+0.21%)
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions PR Newswire - Wed Jun 29, 2022

/PRNewswire/ -- In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the development of...

SPRC : 1.2400 (+2.48%)
DNLI : 15.04 (-3.34%)
SAGE : 13.80 (-1.43%)
SAVA : 21.68 (+4.53%)
ICPT : 19.00 (+0.21%)
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome Globe Newswire - Wed Jun 29, 2022

TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage...

SPRC : 1.2400 (+2.48%)
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder Globe Newswire - Thu Jun 23, 2022

The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment TEL AVIV, Israel, June ...

SPRC : 1.2400 (+2.48%)
SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins Globe Newswire - Wed Jun 15, 2022

JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (the...

SPRC : 1.2400 (+2.48%)

Barchart Exclusives

Guess vs. Levi Strauss: Which Breakout Dividend Stock Is a Better Buy? Barchart - 5 minutes ago
With Levi Strauss and Guess stock prices surging and both apparel giants impressing shareholders with their dividend payments, which of the two is a better buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot